Full Press Release Details
Technologies Enters Europe:
a Strategic Agreement With Waas Group for the Deployment of
1,040 ART Systems in Spain and Portugal
agreement to potentially provide $66 million to Inspira
over a 7-year period, subject to regulatory approval
Israel, October 26, 2021 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira
Technologies"), a groundbreaking respiratory support technology company, announced today that it has signed an exclusive distribution
agreement with Anita T cnica S.L. (WAAS Group), one of Spain's leading distributors and technical service providers of medical
equipment and supplies. WAAS Group provides services to more than 40 international companies and devices, including respiratory
systems for Siemens Healthineers AG ADR (Nasdaq: SMMNY) and Dr gerwerk AG & Co. KGaA, Dr gerwerk AG.
agreement has an initial term of 7 years, subject to completion of product development and regulatory approval. The parties will
collaborate on the marketing and deployment of the ART device, designed to treat deteriorating respiratory failure patients, while they
are awake and breathing. The ART, an early extracorporeal respiratory support system, has the potential to minimize the need for mechanical
ventilation across Spain and Portugal.
to the agreement, Anita T cnica S.L. (WAAS Group) is committed to purchase a minimum of 1040 ART devices and 35,360
disposable units for deployment at hospitals and medical centers within a seven-year period, subject to regulatory approval for the sale
and marketing of the ART devices in Spain and Portugal.
and Spain are important markets in Europe that have extensive experience operating extracorporeal technologies. We see this as an advantage
in ensuring the rapid penetration and adoption of our innovative ART device by the local medical community. The WAAS Group's team
has an impressive record in penetrating the local market with innovative products and leveraging them within the medical community"
stated Joe Hayon, Inspira Technologies' Co-Founder, President and Chief Financial Officer.
Sanz, WAAS Group's CEO, stated: "This agreement represents an exciting opportunity for us to expand our offering of innovative
products to the medical community and patient population in Spain and Portugal. ART is a disruptive technology that can potentially change
how the world plans to treat patients with respiratory failure."
Inspira Technologies OXY B.H.N. Ltd.
Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective
early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory
patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are
awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not
yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).
more information, please visit our corporate website: www.inspirao2.com
Anita T cnica S.L. (WAAS Group)
TECNICA S.L. is located in MADRID, Spain. Anita T cnica S.L. (WAAS Group) is one of Spain's leading distributors and technical
service providers of medical equipment and supplies. WAAS Group provides services to more than 40 international companies and devices,
including respiratory systems.
Statement Disclaimer
press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company
is using forward-looking statements when it discusses the terms of an exclusive distribution agreement with Anita T cnica S.L.
(WAAS Group), the potential revenue to Inspira and that the ART has the potential to minimize the need for mechanical ventilation across
Spain and Portugal.These forward-looking statements and their implications are based on the current expectations of the management of
the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release
any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's
website, www.sec.gov.
Segal, Investor Relations, MS-IR LLC